Gastritis, duodenitis, intestinal colic, bile duct spasm, cholelithiasis colic, cholangitis, cholelithiasis, and post-cholecystectomy syndrome.

Anticholinergic Agent

Absorption:
Butylbromide : Quaternary salts are poorly absorbed (local concentrations in the GI tract following oral dosing may be high).

Distribution:
Vd: Butylbromide : 128 L.
Protein binding : Butylbromide: ~4% (albumin).

Metabolism : Hepatic.
Bioavailability : Butylbromide : 8%.
Half-life elimination : Butylbromide: ~6 to 11 hours.
Time to peak : Butylbromide: ~2 hours.

Hypersensitivity to scopolamine or any component of the formulation; glaucoma or predisposition to narrow-angle glaucoma; paralytic ileus; prostatic hypertrophy; pyloric obstruction; tachycardia secondary to cardiac insufficiency or thyrotoxicosis.

Scopolamine crosses the placenta.

Scopolamine is present in breast milk.
The Academy of Breastfeeding Medicine (ABM) states that scopolamine used as an antiemetic in the perioperative period is likely safe; however, because scopolamine may cause maternal sedation and adversely affect milk supply with repeated doses, other agents may be preferred

Xerostomia、Dizziness、Drowsiness、Agitation、Confusion、Mydriasis、Visual impairment、Pharyngitis

10 to 20 mg 3 to 5 times/day as needed; maximum: 60 mg/day.
When used for chronic symptom control, 10 mg 3 to 5 times/day as needed is recommended.

No dosage adjustment

There are no dosage adjustments provided in the manufacturer's labeling.